Marinus Pharmaceuticals Inc (MRNS) has disclosed a new risk, in the Litigation & Legal Liabilities category.
Marinus Pharmaceuticals Inc. faces a significant business risk due to a securities class action lawsuit filed on June 5, 2024, alleging violations related to misleading statements in their RAISE clinical trials. This lawsuit could result in substantial financial damages and divert critical management resources, potentially impacting the company’s operations and financial health. The outcome remains uncertain, and defending against the lawsuit will likely be costly. If Marinus is required to bear costs beyond their insurance coverage, it could adversely affect their business and stock price.
The average MRNS stock price target is $1.80, implying 495.43% upside potential.
To learn more about Marinus Pharmaceuticals Inc’s risk factors, click here.
Trending Articles
- Deutsche Bank Pounds the Table on Tesla Stock
- ‘Breath of Fresh Air,’ Says Daniel Ives About Rivian Stock
- ‘It’s Not Too Late to Load Up,’ Says Analyst About Nvidia Stock
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
